- May 16, 2012
- Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Directors
- May 15, 2012
- Liquidia Technologies Inc. Studies Show PRINT® Engineered Particles Hold Promise in the Delivery of Respiratory Therapeutics
- May 15, 2012
- Achillion gets FDA incentives for hepatitis C drug
- May 3, 2012
- Liquidia Founder Dr. Joseph DeSimone Elected into National Academy of Sciences
- May 1, 2012
- Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
- April 19, 2012
- Syndax Pharmaceuticals Inc. Appoints Arlene Morris as CEO
- April 6, 2012
- Liquidia figuring out how to ‘unleash’ technology
- April 6, 2012
- Orphan Diseases and the Future of BioPharma, the Focus of the 2012 Orphan Disease Forum
- April 3, 2012
- Liquidia CEO to Participate in Biotech Panel to Explore “How to Create 54 Liquidias”
- April 2, 2012
- Big business appeal of nanotechnology on display in Durham
- March 27, 2012
- Athersys gets OK for German solid organ transplant clinical trial
- March 26, 2012
- Tesaro promises rapid progress with cancer drugs in $86M IPO
- March 21, 2012
- Stem Cell Therapy Holds Promise for Strokes
- March 14, 2012
- Marina, ProNAi in cancer deal
- March 14, 2012
- Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 MPS 7
- March 9, 2012
- Ultragenyx Announces the Completion of the Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
- March 5, 2012
- Milestone Pharmaceuticals Appoints Paul Truex to the Board of Directors
- February 29, 2012
- BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
- February 29, 2012
- Selventa Granted Patent for Discovery of Biomarker Profiles
- February 28, 2012
- FDA grants orphan drug designation to Ultragenyx UX003 for treatment of MPS 7
- February 21, 2012
- Plexxikon receives European approval for Zelboraf
- February 21, 2012
- Diabetes drug developer Lumena raises $2.5M; compound regulates blood sugar
- February 16, 2012
- First and Only Personalized Treatment for Deadliest Form of Skin Cancer Approved by Health Canada
- February 6, 2012
- Transplant antiviral strong in phase 2; Chimerix plans phase 3 start this year
- February 2, 2012
- Athersys, Inc. Announces Positive Results of MultiStem(R) Clinical Trial for Hematopoietic Stem Cell Transplant Support and Prevention of Graft-Versus-Host Disease
- January 27, 2012
- Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
- January 19, 2012
- Researchers uncover how new melanoma drug accelerates secondary skin cancers
- January 19, 2012
- PRINTed Nanoparticles Delivery Multiple Punches to Treat Prostate Cancer
- January 4, 2012
- Achillion hepatitis drug gets faster FDA review